{"id":21728,"date":"2022-07-14T16:34:45","date_gmt":"2022-07-14T14:34:45","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=21728"},"modified":"2022-07-14T16:34:54","modified_gmt":"2022-07-14T14:34:54","slug":"bioinvent-has-carried-out-a-directed-issue","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/bioinvent-has-carried-out-a-directed-issue\/","title":{"rendered":"BioInvent has carried out a directed issue"},"content":{"rendered":"<p class=\"preamble\">BioInvent has carried out a directed placement of new shares of approximately MSEK 300 to international and Swedish institutional investors.<\/p>\n<p>BioInvent is a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer. BioInvent\u2019s shares are listed on Nasdaq Stockholm (BINV).<\/p>\n<p>BioInvent was represented by Mannheimer Swartling.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioInvent has carried out a directed placement of new shares of approximately MSEK 300 to international and Swedish institutional investors. BioInvent is a clinical stage\u2026<\/p>\n","protected":false},"author":7,"featured_media":20283,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-21728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":21728,"sv":21726},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21728"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=21728"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21728\/revisions"}],"predecessor-version":[{"id":21729,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21728\/revisions\/21729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/20283"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=21728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=21728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=21728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}